Participated · Series A · Jul 2026

DeweyLearn develops multimodal AI that ingests classroom audio, video, and learning data to generate actionable insights on instruction and learner performance. Its platform is applied across clinical and healthcare education, higher education, workforce learning, and K-12 in both physical and online settings. DeweyLearn says it can observe and evaluate real learning in action and return expert-level feedback at scale, and it reports grading more than 20,000 student homework submissions at Auguste Escoffier School of Culinary Arts to date. The company won the 2026 ASU+GSV Cup, selected from more than 3,000 companies as the top education technology startup. Founders Luyen Chou and Dirk Liebich bring backgrounds in EdTech leadership and applied AI, respectively. The recent Series A financing is intended to help the company scale its multimodal assessment capabilities.

Participated · Series D · Jul 2026

AdvanCell develops targeted alpha radiopharmaceutical therapies built around a proprietary Lead-212 platform that combines secure isotope supply, automated manufacturing and scalable production. Its lead program, ADVC001, is a Lead-212 PSMA-targeted alpha therapy for metastatic prostate cancer that has shown encouraging Phase 1b anti-tumor activity and favorable tolerability and is currently in Phase 2 clinical development. The company emphasizes vertical integration — spanning isotope supply, advanced manufacturing and clinical development — to address supply and manufacturing constraints for targeted alpha therapies. With integrated operations across North America and Australia, AdvanCell plans to expand U.S. manufacturing infrastructure to support Phase 3 development and future commercial demand. The recent US $315 million Series D financing is intended to advance ADVC001 toward registrational development and accelerate the company’s growing pipeline of targeted alpha therapies.

Participated · Series B · Jul 2026

Stealth BioTherapeutics focuses on developing therapies that directly address mitochondrial bioenergetic deficits across rare and age-related diseases. The company’s development portfolio includes elamipretide programs in Barth syndrome, polymerase gamma–related mitochondrial disease and dry age-related macular degeneration, a next-generation clinical candidate bevemipretide for ophthalmic and neurological indications, and preclinical assets SBT-255 and SBT-589 for rare mitochondrial disorders. Its parent, Mighty Therapeutics, achieved FDA approval in September 2025 for the first commercial therapy for Barth syndrome and the first FDA-approved therapy to directly target mitochondria, generating revenue from its lead commercial product. The company plans to use newly secured capital to accelerate commercial launch activities and advance late-stage and pipeline development programs. Financially, current cash, cash equivalents and product revenues are expected to extend runway into 2028, with additional financing drawdowns projected to support cash flow positivity in early 2029.

Led · Series A · Apr 2026

SimpliFed offers virtual breastfeeding and baby feeding support and broader maternal health care from pregnancy through the postpartum period via a secure, HIPAA-compliant telehealth platform. The company connects parents with a network of baby feeding experts and maternal health specialists and operates a proprietary Maternal Health operating system designed for collaboration with healthcare partners. Its platform uses interoperable infrastructure and API-driven technology to integrate with health plans, providers, partners and health systems for secure data exchange and streamlined workflows. SimpliFed intends to expand those partnerships and scale use of its Maternal Health OS following its Series A. The company is led by founder and CEO Andrea Ippolito and is based in New York City. The recent Series A raised over $10M to support platform growth and partner activation.

Participated · Series D · Feb 2026

Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on improving musculoskeletal health through innovative biologic treatments. Its pipeline currently features three clinical candidates: AGA2118 for postmenopausal osteoporosis, AGA2115 for osteogenesis imperfecta, and AGA111 for spinal fusion. The company recently completed enrollment in its Phase 2 ARTEMIS trial of AGA2118 and has initiated dosing in the Phase 2 IDUN trial evaluating AGA2115. Proceeds from its latest financing will also advance these programs and other undisclosed pipeline assets. Headquartered in Westlake Village, California, Angitia leverages extensive bone biology expertise and rational drug design to address clear unmet medical needs in serious musculoskeletal diseases. No commercial products have been approved yet, reflecting the firm’s clinical-stage status.